top of page

35+ YEARS IN MEDICAL DEVICE | PHARMACEUTICAL | BIOTECHNOLOGY | DIAGNOSTICS

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...

Executive Spotlights

Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

Bavarian Nordic to buy Emergent BioSolution’s travel vaccine portfolio for up to $380 mln

1 min read

Durham, NC, February 15, 2023 (Reuters) -- Danish pharmaceuticals company Bavarian Nordic has agreed to buy a portfolio of travel vaccines from Emergent BioSolutions Inc for up to $380 million, it said on Wednesday after delivering an upbeat outlook for 2023.

Read full article here.

Recent Posts

Curevo secures $110 Million series B to advance Amezosvatein Shingles Vaccine

Seattle, WA, March 17, 2025 (Globe Newswire) -- Curevo Vaccine, a clinical-stage biotechnology company specializing in varicella zoster...

Akari Therapeutics appoints Abizer Gaslightwala as President and CEO

Boston and London, March 20, 2025 (Globe Newswire) -- Akari Therapeutics has named Abizer Gaslightwala as its new President and CEO,...

Latigo Biotherapeutics secures $150M series B to advance non-opioid pain treatments

Thousands Oak, CA, March 17, 2025 (PRNewswire) -- Latigo Biotherapeutics, a clinical-stage biotechnology company, has successfully...

Comments

Life Science Headlines

Curevo secures $110 Million series B to advance Amezosvatein Shingles Vaccine

Akari Therapeutics appoints Abizer Gaslightwala as President and CEO

Latigo Biotherapeutics secures $150M series B to advance non-opioid pain treatments

David Pacitti departs Siemens Healthineers to lead Avanos Medical as CEO

AstraZeneca to Acquire EsoBiotec for Up to $1B to Enhance Cancer Cell Therapy Capabilities

Gensaic and Novo Nordisk Forge $354M Partnership to Advance Precision Therapies

Openwater Names Aaron Timm as CEO to Drive Growth in Portable Imaging and Therapy Devices

AbbVie Enters Obesity Drug Race with $2.25B Licensing Deal for Gubra’s Amylin Analog

Nimbus Therapeutics Appoints Abbas Kazimi as CEO Amid Strategic Transition

Roche Strikes $5.3B Deal with Zealand Pharma to Expand in Obesity Market

bottom of page